
BioNTech SE
BNTXHealthcare|Biotechnology|DE
$87.51
+1.65 (+1.92%)
DCF Value
$46.34
Tangible Book / Share
$64.71
Cash / Share
$58.79
Next Earnings Report
Mar 9, 2027
EPS est. -$1.90 · Revenue est. $445.5M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (49)
Dec 2026
Est. completion
P1Non Small Cell Lung Cancer
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752n=80
Jan 2027
Est. completion
P2Neuroendocrine Neoplasm
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
NCT05879055n=31
Apr 2027
Est. completion
May 2027
Est. completion
P2CRC (Colorectal Cancer)
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT07133750n=100
May 2027
Est. completion
P3SCLC
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532n=404
Jun 2027
Est. completion
P2Mpox (Monkeypox)
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
NCT07379580n=310
Jun 2027
Est. completion
P2Extensive-stage Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209n=110
Jul 2027
Est. completion
P3Triple Negative Breast Cancer(TNBC)
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621n=392
Jul 2027
Est. completion
P1Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
NCT03219450n=15
Aug 2027
Est. completion
P1P2HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691n=796
Aug 2027
Est. completion
P1Malignant Solid Tumor
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
NCT06057038n=8
Aug 2027
Est. completion
P1P2Advanced Solid Tumor
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329n=1,123
Aug 2027
Est. completion
P4COVID-19 Vaccines
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
NCT07730450n=200
Aug 2027
Est. completion
P3Non Small Cell Lung Cancer
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510n=630
Nov 2027
Est. completion
P1P2Advanced Solid Tumor
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348n=375
Nov 2027
Est. completion
P2Muscle-invasive Urothelial Carcinoma
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983n=62
Dec 2027
Est. completion
P3HER2-positive Breast Cancer
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
NCT06265428n=228
Dec 2027
Est. completion
P1P2Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116n=862
Dec 2027
Est. completion
P2Pancreatic Ductal Adenocarcinoma (PDAC)
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
NCT07255404n=105
Jan 2028
Est. completion
P2Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT07297212n=75
Awaiting Results (10)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2026
P2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378Oct 2026
P1
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
NCT05432583Aug 2026
P1
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Aug 2026
P3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Mar 2026
P1P2
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
NCT05547464Dec 2025
P1P2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Sep 2024
P2
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
NCT05756972May 2024
P2
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150Recent Press Releases
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Nov 3, 2026 · GlobeNewsWire
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
Oct 26, 2026 · GlobeNewsWire
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Oct 25, 2026 · GlobeNewsWire
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
Oct 22, 2026 · GlobeNewsWire
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
Oct 20, 2026 · GlobeNewsWire
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
Oct 19, 2026 · GlobeNewsWire
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
Oct 14, 2026 · PRNewsWire
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
Oct 13, 2026 · GlobeNewsWire
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
Sep 14, 2026 · GlobeNewsWire
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Aug 27, 2026 · Business Wire
SEC Filings (106)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 3, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Nov 3, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 26, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 26, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 22, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 19, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 13, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 18, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 14, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 28, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 20, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 4, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 4, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 3, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 30, 2026 | 20-F/A | Annual report (foreign) | DocumentIndex |
| Jul 29, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jun 8, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jun 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| May 22, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| May 15, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| May 15, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 7, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| May 5, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| May 5, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Apr 13, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Apr 2, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Apr 1, 2026 | 20-F/A | Annual report (foreign) | DocumentIndex |
| Mar 24, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Mar 10, 2026 | 20-F | Annual report (foreign) | DocumentIndex |
| Mar 10, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Mar 10, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jan 28, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jan 14, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jan 12, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jan 6, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Dec 18, 2025 | SC TO-T/A | Tender offer | DocumentIndex |
| Dec 18, 2025 | 6-K | Foreign issuer report | DocumentIndex |
| Dec 9, 2025 | 6-K | Foreign issuer report | DocumentIndex |